3.jpg)
Eli Lilly and Company will conduct a webcast on Monday, June 19, 2017, to discuss the company's pain management portfolio, including data from three phase 3 studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, and data from one Phase 3 study of lasmiditan, an investigational treatment for the acute treatment of migraine. The webcast will begin at 10 a.m. Eastern time. The phase 3 data will also be presented at the 59th Annual Scientific Meeting of the American Headache Society.
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Lilly will conduct webcast, discuss pain management portfolio
